MedTrace Logo

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

NCT04468165 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2023-09-22

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the effectiveness, safety and health related quality of life of Generic DMF (Sclera® or Marovarex ®, Hikma) in patients undergoing routine clinical care for RRMS in MENA Region

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Dimethyl Fumarate (DMF)

Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2023-07-20
Completion
2023-07-20

Countries

  • Algeria
  • Egypt
  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04468165 on ClinicalTrials.gov